Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to develop itself or out-license for cardiovascular diseases. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. In addition, Cyclerion holds 10 percent equity ownership in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired the brain-penetrant sGC stimulators zagociguat and CY3018.
Company Details
- Employees
- 12
- Founded
- 2019
- Address
- Cambridge, Ma 02142, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cyclerion.com
- Keywords
- Manager jobs.
- HQ
- Cambridge, MA
Cyclerion Questions
Cyclerion's website is http://www.cyclerion.com
Cyclerion's LinkedIn profile is https://www.linkedin.com/company/cyclerion
Cyclerion has
12 employees.
View email and phone details for 12
employees at Cyclerion.
Cyclerion's industry is
Biotechnology Research
Cyclerion's top competitors are
Tisento Therapeutics,
Sarepta Therapeutics,
Rapport Therapeutics,
89bio,
Alnylam Pharmaceuticals,
Ovid Therapeutics,
Oculis,
Cellphire Therapeutics, Inc.,
Ironwood Pharmaceuticals,
Cerevance.
Cyclerion's categories are Biotechnology Research
Cyclerion's founding year is 2019
